What's new

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 16, Status: Authorised

Feb 17, 2025 - 17:21
 0
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 16, Status: Authorised
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 16, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Daptomycin Hospira, da...

Next Article

Human medicines European public assessment report (EPAR): Cibinqo, abrocitinib, ...

Related Posts

Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Krka d.d., emtricitabine,tenofovir disoproxil, Date of authorisation: 28/04/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): ProQuad, measles, mumps, rubella and varicella vaccine (live), Date of authorisation: 05/04/2006, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 26, 2025  0

Human medicines European public assessment report (EPAR): Micardis, telmisartan, Date of authorisation: 16/12/1998, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 26, 2025  0